{"id":459,"title":"Diagnostic Performance of Micro-RNAs as Biomarkers for Endometrial Cancer: A Systematic Review and Meta-Analysis","title_zh":"MicroRNA作为子宫内膜癌诊断生物标志物的诊断效能：系统评价与荟萃分析","url":"https://doi.org/10.12688/f1000research.179155.2","doi":"10.12688/f1000research.179155.2","pmid":null,"journal":"F1000Res","kind":"preprint","lang":"en","published_at":"2026-10-31T00:00:00+00:00","fetched_at":"2026-11-08T03:44:14+00:00","authors":["Putra AD","Rahman AT","Syariatin L","Darmawan NS","Cuandra KN","Hamka MF","Setiya DFJ","Argani AN","Aaliyya ZSA","Widi VSN","Rachmi SN","Huang PK","Silalahi SPDE","Wahyudi DP","Firjatullah MF","Amri DAA","Triasmaja IC","Tristan CD"],"primary_topic":"endometrium","topics":[{"slug":"endometrium","score":4.0,"hits":["endometrial"]},{"slug":"repro-endo","score":1.0,"hits":["dor"]}],"topic_score":4.0,"preference_score":0.0,"preference_labels":[],"llm_score":58.0,"final_score":58.0,"score_dims":{"novelty":45,"rigor":70,"impact":48,"relevance":45,"translation":45},"recommend_reason":"对子宫内膜癌无创诊断标志物提供了较完整的合并证据，但与辅助生殖/胚胎核心场景关联有限，且为预印本、异质性及标准化问题尚存，暂不构成临床实践改变依据。","keywords":["子宫内膜癌","MicroRNA","诊断生物标志物","荟萃分析","诊断准确性"],"selected":0,"story_id":245,"llm_provider":"deepseek","llm_model":"deepseek-flash","llm_effort":"low","source_key":"europepmc-preprints","source_name":"Europe PMC · 预印本（领域内）","source_tier":1,"mention_count":1,"has_interpretation":false,"journal_key":null,"journal_tier":"unknown","journal_if":null,"is_mock":false,"summary_zh":"该预印本系统评价与荟萃分析纳入11篇文章，分别合并单-miRNA与多-miRNA panel对子宫内膜癌的诊断准确性。单-miRNA的合并敏感度0.90、特异度0.87、AUC 0.95；多-miRNA panel敏感度0.92、特异度0.95、AUC 0.95。作者认为miRNA标志物具较好鉴别能力，但证据尚不足以常规临床使用，需前瞻性多中心验证与标准化检测。","summary":"Background: Endometrial cancer (EC) is a common gynecologic malignancy with a growing need for accurate, minimally invasive diagnostic biomarkers. MicroRNAs (miRNAs) are stable across multiple biological specimens and have emerged as promising diagnostic candidates. This meta-analysis evaluated the diagnostic performance of single-miRNA biomarkers and multi-miRNA panels for EC. Methods A systematic review and diagnostic test accuracy meta-analysis was conducted according to PRISMA 2020. PubMed/MEDLINE, Embase, Web of Science, and ScienceDirect were searched through August 2025. Only one diagnostic estimate per independent participant cohort was included within each co-primary analysis. Single-miRNA biomarkers and multi-miRNA panels were analyzed separately using bivariate random-effects models. Pooled sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio (DOR), and SROC AUC were estimated. Results Eleven articles were included. Eight independent estimates contributed to the single-miRNA analysis and five to the multi-miRNA panel analysis. Single miRNAs yielded a pooled sensitivity of 0.90 (95% CI 0.82–0.95), specificity of 0.87 (0.75–0.94), DOR of 59.96 (18.59–193.37), and AUC of 0.95 (0.92–0.96). Multi-miRNA panels showed a sensitivity of 0.92 (0.87–0.95), specificity of 0.95 (0.88–0.98), DOR of 212.96 (67.84–668.52), and AUC of 0.95 (0.93–0.97). Sensitivity analyses supported the overall robustness of the findings. Conclusions MiRNA-based biomarkers show promising diagnostic discrimination for EC, but current evidence remains insufficient for routine clinical implementation. Prospective multicenter validation with standardized assays and prespecified thresholds is required.","interpretation_basis":null,"fulltext_status":null,"interpretation":null,"fulltext":{"available":false,"status":null,"reason":"尚未抓取全文（未入选、分数未达阈值，或还没跑 fulltext 步骤）","pmcid":null,"license":null,"chars":0,"source":null,"fetched_at":null}}